News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
52 Results
Section
Business (9)
Drug Development (9)
News (17)
Tag
Alliances (2)
Cardiovascular disease (1)
Clinical research (12)
Collaboration (2)
COVID-19 (1)
Data (5)
Diabetes (1)
Earnings (5)
Events (15)
GLP-1 (1)
Healthcare (1)
Indications (1)
Infectious disease (1)
IPO (2)
Metabolic disorders (4)
Obesity (2)
Patient recruitment (1)
People (6)
Phase 1 (8)
Phase 2 (5)
Pipeline (6)
Preclinical (3)
Date
Last 30 days (3)
Last 365 days (16)
2026 (3)
2025 (14)
2024 (13)
2023 (3)
2022 (10)
2021 (6)
2020 (3)
Location
Asia (1)
California (21)
Northern California (18)
United States (21)
52 Results for "@bioagelabs".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
·
1 min read
Press Releases
BioAge Labs to Present at Jefferies 2025 Global Healthcare Conference in London
November 10, 2025
·
1 min read
Press Releases
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
January 21, 2026
·
8 min read
Press Releases
BioAge Announces Proposed Public Offering
January 21, 2026
·
5 min read
Press Releases
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
January 13, 2026
·
9 min read
Press Releases
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
December 5, 2025
·
8 min read
Press Releases
BioAge Labs to Present at Upcoming September 2025 Investor Conferences
August 21, 2025
·
1 min read
Press Releases
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 6, 2025
·
10 min read
Press Releases
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
August 18, 2025
·
7 min read
Press Releases
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
June 23, 2025
·
7 min read
1 of 6
Next
